Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PC-0061 is a long-acting microsphere injection formulation of **naltrexone**, a small molecule opioid receptor antagonist. Developed by **Changtai Pharmaceutical** (also known as **PharmaMax Corp**), it is specifically designed for the treatment of **opioid dependence** and **alcohol dependence**. The drug utilizes a microsphere delivery system to provide sustained release of the active ingredient over an extended period, typically one month, following a single intramuscular injection. This long-acting formulation aims to improve patient compliance and treatment outcomes by eliminating the need for daily oral dosing, which is a significant challenge in addiction recovery. Naltrexone works by competitively binding to mu-opioid receptors in the central nervous system, thereby blocking the euphoric and reinforcing effects of exogenous opioids and reducing alcohol cravings by modulating the brain's reward pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PC-0061.